{
    "clinical_study": {
        "@rank": "36698", 
        "acronym": "DARE-C", 
        "arm_group": [
            {
                "arm_group_label": "Group A - 8 weeks total therapy", 
                "arm_group_type": "Experimental", 
                "description": "8 weeks total therapy of TPV/PEG-IFN/RBV if undetectable HCV RNA after 2 weeks of therapy"
            }, 
            {
                "arm_group_label": "Group B - 12 weeks total therapy", 
                "arm_group_type": "Experimental", 
                "description": "12 weeks  total therapy of TPV/PEG-IFN/RBV if undetectable HCV RNA after 4 weeks of therapy"
            }, 
            {
                "arm_group_label": "Group C - 24 weeks total therapy", 
                "arm_group_type": "Experimental", 
                "description": "24 weeks total therapy - TPV/PEG-IFN/RBV for 12 weeks + PEG-IFN/RBV for 12 weeks if undetectable HCV RNA after 8 weeks of therapy"
            }
        ], 
        "brief_summary": {
            "textblock": "To examine the safety and efficacy of response guided triple therapy (PEG-IFN, Ribavirin,\n      Telaprevir) for the treatment of early chronic HCV infection."
        }, 
        "brief_title": "DAA Based Therapy for Recently Acquired Hepatitis C (DARE-C)", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Early Chronic Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "DARE-C is a prospective open label multi-centre pilot study examining the safety and\n      efficacy of response guided triple therapy (PEG-IFN, Ribavirin and Telaprevir) for the\n      treatment of early chronic HCV genotype 1 infection in individuals with and without HIV\n      infection."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Provision of written, informed consent.\n\n          2. HCV genotype 1 infection\n\n          3. Quantifiable HCV RNA at screening and baseline (>10,000 IU/ml)\n\n          4. Recent hepatitis C infection with an estimated duration of Infection >6 months and \u2264\n             18 months defined as A) i) First anti-HCV antibody or HCV RNA positive within the\n             previous 6 months and ii) Documented anti-HCV antibody negative or HCV RNA negative\n             within the 24 months prior to anti-HCV antibody positive result OR B) i) First\n             anti-HCV antibody or HCV RNA positive within the previous 6 months and ii) acute\n             clinical hepatitis (jaundice or ALT> 10 X ULN) within the 12 months prior to first\n             positive HCV antibody or HCV RNA with no other cause of acute hepatitis identifiable\n\n          5. Compensated liver disease (Child-Pugh A)\n\n          6. Negative pregnancy test at screening and 24 hours prior to the first dose of study\n             drugs.\n\n          7. If heterosexually active, a female subject of childbearing potential and a\n             nonvasectomized male subject who has a female partner of childbearing potential must\n             agree to use 2 effective contraceptives from screening onwards until 6 months (female\n             subject) or 7 months (male subject) after RBV therapy has ended. Note: Hormonal\n             contraceptives may be continued but may not be reliable during telaprevir dosing and\n             for 2 months following cessation of telaprevir. Therefore, subjects should agree to\n             use 2 effective non-hormonal methods of contraception during telaprevir combination\n             therapy and for 2 months after the last intake of telaprevir. As of two months after\n             completion of telaprevir hormonal contraceptives can again be used as one of the two\n             required effective methods of birth control.\n\n          8. Subject is judged to be medically stable on the basis of physical examination,\n             medical history and vital signs.\n\n          9. Adequate English to provide written, informed consent and to provide reliable\n             responses to the study interview\n\n        Additional inclusion criteria for HIV positive individuals\n\n          -  Confirmed HIV infection > 6 months duration\n\n          -  CD4 > 200 cells/mm3 and HIV < 50 c/ml on stable ART at least 3 months prior to\n             treatment\n\n          -  Or\n\n          -  CD4 >= 500 cells/mm3 and HIV VL < 100,000 not on ART\n\n          -  If on ART must be taking a regimen containing an accepted* combination of the\n             following drugs: tenofovir ( TDF), lamivudine ( 3TC), emtricitabine (FTC), efavirenz\n             (EFV), abacavir (ABC), raltegravir (RAL), etravirine (ETV), rilpivirine (RIL),\n             ritonavir boosted atazanavir (r/ATZ) * Combination must be supported by current HIV\n             treatment guidelines\n\n        Exclusion Criteria:\n\n          -  Individuals considered by the study investigators to be unlikely to participate in\n             intensive follow-up and/or unwilling to provide extra blood samples\n\n          -  Current injecting drug use (any injecting within previous 4 weeks)\n\n          -  Standard exclusions to Peg-interferon (PEG-IFN), Ribavirin (RBV) and Telaprevir (TPV)\n             therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01743521", 
            "org_study_id": "VHCRP1102", 
            "secondary_id": "VX-950HCP4010"
        }, 
        "intervention": {
            "arm_group_label": [
                "Group A - 8 weeks total therapy", 
                "Group B - 12 weeks total therapy", 
                "Group C - 24 weeks total therapy"
            ], 
            "description": "Drug Telaprevir (TPV): dosed 1125mg twice daily (given as three 375 mg film-coated tablets) orally, except in the situation where a patient is on efavirenz in which case the dose of telaprevir will be 1125mg three times daily.\nDrug Ribavirin (RBV): 1000mg or 1200mg p.o daily in split doses (1000mg for patients weighing <75kg and 1200mg for patients weighing \u2265 75kg).\nDrug PEG-IFN (other name: Pegasys): 180mcg in 0.5ml (pre-filled syringes) administered subcutaneously once weekly.", 
            "intervention_name": "TPV/PEG-IFN/RBV", 
            "intervention_type": "Drug", 
            "other_name": [
                "Telaprevir brand name: INCIVO", 
                "Ribavirin brand name: COPEGUS", 
                "PEG-IFN brand name: PEGASYS"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Ribavirin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Hepatitis C", 
            "Individualised therapy", 
            "Response-guided therapy", 
            "Telaprevir", 
            "PEG-IFN", 
            "Ribavirin", 
            "Hepatitis"
        ], 
        "lastchanged_date": "December 10, 2013", 
        "location": [
            {
                "contact": {
                    "email": "rhickey@stvincents.com.au", 
                    "last_name": "Rebecca Hickey", 
                    "phone": "+61 2 8382 3825"
                }, 
                "facility": {
                    "address": {
                        "city": "Sydney", 
                        "country": "Australia", 
                        "state": "New South Wales", 
                        "zip": "2010"
                    }, 
                    "name": "St Vincent's Hospital"
                }, 
                "investigator": {
                    "last_name": "Gregory Dore, MBBS FRACP", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "catherine.ferguson@health.sa.gov.au", 
                    "last_name": "Catherine Ferguson", 
                    "phone": "+61 8 8222 5635"
                }, 
                "facility": {
                    "address": {
                        "city": "Adelaide", 
                        "country": "Australia", 
                        "state": "South Australia", 
                        "zip": "5000"
                    }, 
                    "name": "Royal Adelaide Hospital"
                }, 
                "investigator": {
                    "last_name": "David Shaw", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "svonbibra@burnet.edu.au", 
                    "last_name": "Sally von Bibra", 
                    "phone": "+61 3 9282 2261"
                }, 
                "facility": {
                    "address": {
                        "city": "Melbourne", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3004"
                    }, 
                    "name": "The Alfred Hospital"
                }, 
                "investigator": {
                    "last_name": "Margaret Hellard", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Australia"
        }, 
        "number_of_arms": "3", 
        "official_title": "DAA Based Therapy for Recently Acquired Hepatitis C", 
        "overall_official": {
            "affiliation": "The Kirby Institute", 
            "last_name": "Gail Matthews, MbChB, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Proportion of subjects achieving SVR 12 (negative qualitative HCV RNA 12 weeks after therapy completion)", 
            "measure": "SVR12", 
            "safety_issue": "No", 
            "time_frame": "12 weeks post-treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01743521"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To evaluate the proportion of patients with undetectable HCV RNA 24 weeks after therapy completion (SVR24)", 
                "measure": "SVR24", 
                "safety_issue": "No", 
                "time_frame": "24 weeks post-treatment"
            }, 
            {
                "description": "To evaluate the proportion of patients with undetectable HCV RNA at end of treatment (ETR)", 
                "measure": "Undetectable HCV RNA (ETR)", 
                "safety_issue": "No", 
                "time_frame": "Wk 8 (Group A), Wk 12 (Group B), Wk 24 (Group C)"
            }, 
            {
                "description": "To evaluate the proportion of patients with undetectable HCV RNA at weeks 1, 2, 3, 4, 5, 6 and 8 of therapy.", 
                "measure": "Undetectable HCV RNA (weeks 1,2,3,4,5,6,8)", 
                "safety_issue": "No", 
                "time_frame": "Week 1,2,3,4,5,6 and 8 of therapy"
            }, 
            {
                "description": "To examine treatment outcome by IL28B polymorphism", 
                "measure": "gene IL28B polymorphism", 
                "safety_issue": "No", 
                "time_frame": "Baseline"
            }, 
            {
                "description": "To correlate the presence and frequency of baseline resistance-associated variants (RAVs) with the response of Telaprevir based therapy for early chronic HCV infection.", 
                "measure": "Baseline resistance-associated variants", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Wk 8 (Group A), Wk 12 (Group B), Wk 24 (Group C)"
            }, 
            {
                "description": "To examine the emergence of resistance-associated variants during telaprevir based therapy for early chronic infection", 
                "measure": "Resistance-associated variants", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Wk 8 (Group A), Wk 12 (Group B), Wk 24 (Group C)"
            }, 
            {
                "description": "To evaluate indicators of toxicity (ALT, HB, Neutrophils, Platelets) during telaprevir based therapy", 
                "measure": "Indicators of toxicity (ALT, HB, Neutrophils, Platelets)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, Wk 8 (Group A), Wk 12 (Group B), Wk 24 (Group C)"
            }, 
            {
                "description": "To correlate plasma ribavirin levels with treatment outcome and changes in haemoglobin during therapy", 
                "measure": "Plasma ribavirin levels and haemoglobin", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, Wk 8 (Group A), Wk 12 (Group B), Wk 24 (Group C)"
            }, 
            {
                "description": "In HIV positive participants to evaluate changes in CD4 counts and HIV RNA during telaprevir based therapy", 
                "measure": "CD4 and HIV RNA", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, Wk 8 (Group A), Wk 12 (Group B), Wk 24 (Group C)"
            }
        ], 
        "source": "Kirby Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "Janssen-Cilag Ltd.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Kirby Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}